查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1620699

肺炎链球菌疫苗市场：按类型、适应症、年龄层、分布 - 全球预测 2025-2030

Pneumococcal Vaccine Market by Type (Conjugate Vaccines, Polysaccharide Vaccines), Indication (Bronchitis, Meningitis, Pneumonia), Age Group, Distribution - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年肺炎链球菌疫苗市值为107.3亿美元，预计2024年将达到115.6亿美元，复合年增长率为7.92%，预计到2030年将达到183亿美元。

肺炎链球菌疫苗市场的目标是预防肺炎球菌引起的感染疾病，这对于降低所有年龄段，特别是婴幼儿、老年人和免疫力人群的发病率和死亡率至关重要。该市场包括结合疫苗和多醣疫苗等多种类型的疫苗，主要应用于儿童、成人和特定风险族群的免疫计划。最终用户主要是医疗保健提供者、政府卫生部门和进行疫苗试验的研究机构。目前，市场发展是由人们对肺炎链球菌感染的认识提高、政府免疫工作以及疫苗开发技术进步所推动的。值得注意的机会包括扩大免疫率低的新兴经济体的疫苗覆盖率，以及利用疫苗技术的进步来提高针对更广泛病毒株的覆盖率和功效。然而，市场发展面临开发成本高、监管指南严格和疫苗分配挑战等限制，特别是在低收入地区。此外，疫苗有效性的变化和非疫苗血清型的出现也可能阻碍广泛使用。下一代疫苗的开发有创新机会，例如口服疫苗和微针阵列，具有更广泛的保护范围和改进的给药方法。此外，专注于增强针对抗药性菌株的疫苗功效的研究和开发可以提供显着的市场优势。由于市场的性质，竞争非常激烈，辉瑞（Pfizer）、默克（Merck）和GlaxoSmithKline Plc）等主要参与者处于领先地位，但专注于负担得起且易于使用的解决方案的新进入者也有空间。与公共卫生机构的合作以及对研发的投资可能会促进市场进入和扩张。因此，重要的是要跟上技术进步、监管变化和不断变化的感染疾病模式，以利用潜在的机会并克服当前的挑战。

主要市场统计
基准年[2023] 107.3亿美元
预测年份 [2024] 115.6亿美元
预测年份 [2030] 183亿美元
复合年增长率（%） 7.92%

市场动态：快速发展的肺炎球菌疫苗市场的关键市场洞察

供需的动态交互作用正在改变肺炎球菌疫苗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时也能帮助企业了解消费行为及其对製造业的影响。

  • 市场驱动因素
    • 肺炎链球菌疾病的盛行率增加
    • 加强对肺炎链球菌疫苗接种的意识提升计划
  • 市场限制因素
    • 开发肺炎链球菌疫苗高成本
  • 市场机会
    • 推出新型肺炎链球菌疫苗，可广泛预防各种细菌菌株
    • 完善低温运输网络，拓展新型配送体系发展
  • 市场挑战
    • 疫苗生产临床试验的延误

波特五力：驾驭肺炎链球菌疫苗市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解肺炎链球菌疫苗市场的外部影响

外部宏观环境因素在塑造肺炎球菌疫苗市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助企业预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解肺炎链球菌疫苗市场的竞争状况

肺炎链球菌疫苗市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV 定位矩阵肺炎链球菌疫苗市场供应商的绩效评估

FPNV定位矩阵是评估肺炎链球菌疫苗市场供应商的关键工具。此矩阵允许业务组织根据供应商的商务策略和产品满意度评估供应商，从而做出符合其目标的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了肺炎球菌疫苗市场的成功之路

对于旨在加强在全球市场的影响力的公司来说，肺炎球菌疫苗市场的策略分析至关重要。透过考虑关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：对当前市场环境的详细审查、主要企业的广泛资料、对其在市场中的影响力和整体影响力的评估。

2. 市场开发：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、未开发地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 肺炎链球菌感染的传播
      • 加强肺炎链球菌疫苗接种的认识计划
    • 抑制因素
      • 研发肺炎链球菌疫苗成本高昂
    • 机会
      • 推出新型肺炎链球菌疫苗，针对不同菌株提供更广泛的保护
      • 完善低温运输网络，拓展新型配送体系发展
    • 任务
      • 疫苗生产临床试验处理缓慢
  • 市场区隔分析
    • 类型：增加使用产生强烈免疫反应（包括记忆反应）的结合疫苗
    • 分发：透过政府当局扩大肺炎球菌疫苗的供应，并提高高风险族群的疫苗接种率
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章 肺炎链球菌疫苗市场：依类型

  • 结合疫苗
  • 多醣体疫苗

第七章 肺炎链球菌疫苗市场适应症

  • 支气管炎
  • 脑膜炎
  • 肺炎
  • 败血症

第八章肺炎链球菌疫苗市场：依年龄组别

  • 成人
  • 婴幼儿

第九章 肺炎链球菌疫苗市场经销商

  • 政府机关
  • 非政府组织

第十章美洲肺炎链球菌疫苗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太肺炎链球菌疫苗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲肺炎链球菌疫苗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准默克新型肺炎链球菌疫苗提供广泛保护
    • Vaxcyte 透过加强与 Lonza 在肺炎链球菌疫苗生产方面的合作来加强全球供应链
    • FDA核准辉瑞 Prevenar 20，这是预防肺炎链球菌感染的重大突破
  • 战略分析和建议

公司名单

  • AstraZeneca PLC
  • Biological E. Limited
  • Biovac
  • CSL Limited
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Incepta Pharmaceuticals Ltd.
  • Lonza AG
  • Merck & Co., Inc.
  • Panacea Biotec Limited
  • Pfizer, Inc.
  • Sanofi SA
  • Serum Institute of India Pvt. Ltd.
  • Vaxcyte Inc.
  • Walvax Biotechnology Co., Ltd.
Product Code: MRR-43539E5D3200

The Pneumococcal Vaccine Market was valued at USD 10.73 billion in 2023, expected to reach USD 11.56 billion in 2024, and is projected to grow at a CAGR of 7.92%, to USD 18.30 billion by 2030.

The pneumococcal vaccine market, targeting prevention of infections caused by Streptococcus pneumoniae bacteria, is pivotal in reducing morbidity and mortality rates across all age groups, particularly among infants, the elderly, and individuals with compromised immune systems. The scope of the market encompasses various vaccine types such as conjugate and polysaccharide vaccines, with applications primarily in immunization schedules for children, adults, and specific at-risk populations. End-users are primarily healthcare providers, government health departments, and research organizations conducting vaccine trials. Currently, market growth is driven by increasing awareness of pneumococcal diseases, governmental immunization initiatives, and technological advancements in vaccine development. Notable opportunities include expanding the vaccine's reach in emerging economies with lower immunization rates and leveraging advancements in vaccine technology for broader strain coverage and enhanced efficacy. Market growth, however, faces limitations such as high development costs, stringent regulatory guidelines, and challenges in vaccine distribution logistics, particularly in low-income regions. Additionally, varying vaccine efficacy rates and the emergence of non-vaccine serotype strains could hinder widespread adoption. Innovation opportunities exist in developing next-generation vaccines with broader protective profiles and improved administration methods, such as oral vaccines or micro-needle arrays. Furthermore, research and development focusing on enhancing vaccine efficacy against resistant strains could offer significant market advantages. The market's nature is competitive with key players like Pfizer, Merck, and GlaxoSmithKline leading developments, but there is room for new entrants focusing on affordable and accessible solutions. Collaborative efforts with public health entities and investments in R&D can facilitate market entry and expansion. Consequently, staying abreast of technological advancements, regulatory changes, and shifting infectious disease patterns is crucial for leveraging potential opportunities and overcoming present challenges.

KEY MARKET STATISTICS
Base Year [2023] USD 10.73 billion
Estimated Year [2024] USD 11.56 billion
Forecast Year [2030] USD 18.30 billion
CAGR (%) 7.92%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Pneumococcal Vaccine Market

The Pneumococcal Vaccine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing prevalence of pneumococcal diseases
    • Rising awareness programs regarding the use of pneumococcal vaccination
  • Market Restraints
    • High cost associated with the development of pneumococcal vaccines
  • Market Opportunities
    • Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
    • Improving cold chain networks and growing development of novel delivery systems
  • Market Challenges
    • Slow processing of clinical trials for the production of vaccine

Porter's Five Forces: A Strategic Tool for Navigating the Pneumococcal Vaccine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Pneumococcal Vaccine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Pneumococcal Vaccine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Pneumococcal Vaccine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Pneumococcal Vaccine Market

A detailed market share analysis in the Pneumococcal Vaccine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Pneumococcal Vaccine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Pneumococcal Vaccine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Pneumococcal Vaccine Market

A strategic analysis of the Pneumococcal Vaccine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Pneumococcal Vaccine Market, highlighting leading vendors and their innovative profiles. These include AstraZeneca PLC, Biological E. Limited, Biovac, CSL Limited, F. Hoffmann-La Roche AG, GlaxoSmithKline plc, Incepta Pharmaceuticals Ltd., Lonza AG, Merck & Co., Inc., Panacea Biotec Limited, Pfizer, Inc., Sanofi SA, Serum Institute of India Pvt. Ltd., Vaxcyte Inc., and Walvax Biotechnology Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Pneumococcal Vaccine Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Conjugate Vaccines and Polysaccharide Vaccines.
  • Based on Indication, market is studied across Bronchitis, Meningitis, Pneumonia, and Sepsis.
  • Based on Age Group, market is studied across Adults and Infants & Young Children.
  • Based on Distribution, market is studied across Government Authorities and Non-Governmental Organizations.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence of pneumococcal diseases
      • 5.1.1.2. Rising awareness programs regarding the use of pneumococcal vaccination
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with the development of pneumococcal vaccines
    • 5.1.3. Opportunities
      • 5.1.3.1. Introduction of novel pneumococcal vaccines for broader protection against various bacteria strains
      • 5.1.3.2. Improving cold chain networks and growing development of novel delivery systems
    • 5.1.4. Challenges
      • 5.1.4.1. Slow processing of clinical trials for the production of vaccine
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing usage of conjugate vaccines to produce a strong immune response that includes a memory response
    • 5.2.2. Distribution: Growing availability of pneumococcal vaccine through government authorities for enhancing vaccination coverage among at-risk populations
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Pneumococcal Vaccine Market, by Type

  • 6.1. Introduction
  • 6.2. Conjugate Vaccines
  • 6.3. Polysaccharide Vaccines

7. Pneumococcal Vaccine Market, by Indication

  • 7.1. Introduction
  • 7.2. Bronchitis
  • 7.3. Meningitis
  • 7.4. Pneumonia
  • 7.5. Sepsis

8. Pneumococcal Vaccine Market, by Age Group

  • 8.1. Introduction
  • 8.2. Adults
  • 8.3. Infants & Young Children

9. Pneumococcal Vaccine Market, by Distribution

  • 9.1. Introduction
  • 9.2. Government Authorities
  • 9.3. Non-Governmental Organizations

10. Americas Pneumococcal Vaccine Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Pneumococcal Vaccine Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Pneumococcal Vaccine Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Merck's New Pneumococcal Vaccine Targeting Broad Protection
    • 13.3.2. Vaxcyte Bolsters Global Supply Chain with Enhanced Lonza Collaboration for Pneumococcal Vaccine Production
    • 13.3.3. FDA Approves Pfizer's Prevnar 20 a Significant Advancement in Pneumococcal Disease Prevention
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AstraZeneca PLC
  • 2. Biological E. Limited
  • 3. Biovac
  • 4. CSL Limited
  • 5. F. Hoffmann-La Roche AG
  • 6. GlaxoSmithKline plc
  • 7. Incepta Pharmaceuticals Ltd.
  • 8. Lonza AG
  • 9. Merck & Co., Inc.
  • 10. Panacea Biotec Limited
  • 11. Pfizer, Inc.
  • 12. Sanofi SA
  • 13. Serum Institute of India Pvt. Ltd.
  • 14. Vaxcyte Inc.
  • 15. Walvax Biotechnology Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. PNEUMOCOCCAL VACCINE MARKET RESEARCH PROCESS
  • FIGURE 2. PNEUMOCOCCAL VACCINE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. PNEUMOCOCCAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. PNEUMOCOCCAL VACCINE MARKET DYNAMICS
  • TABLE 7. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY CONJUGATE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY POLYSACCHARIDE VACCINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY BRONCHITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY MENINGITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY PNEUMONIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY SEPSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY ADULTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INFANTS & YOUNG CHILDREN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY GOVERNMENT AUTHORITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL PNEUMOCOCCAL VACCINE MARKET SIZE, BY NON-GOVERNMENTAL ORGANIZATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 26. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 30. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 34. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 38. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 42. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 47. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 52. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 56. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 60. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 64. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 68. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 72. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 76. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 80. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 84. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 88. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 92. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 96. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 109. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 113. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 117. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 121. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 125. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 129. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 133. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 137. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 141. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 145. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 149. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 153. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 157. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 161. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 165. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 169. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 173. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 177. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 181. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY AGE GROUP, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM PNEUMOCOCCAL VACCINE MARKET SIZE, BY DISTRIBUTION, 2018-2030 (USD MILLION)
  • TABLE 189. PNEUMOCOCCAL VACCINE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 190. PNEUMOCOCCAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2023